Demographic characteristics of CML study patients with CCR
Characteristic . | Value . |
|---|---|
| Median age, y (range) | 51.8 (20-74) |
| Sex, % male | 60 |
| Median time from leukemia diagnosis to start of imatinib mesylate, mo (range) | 8.9 (0-165) |
| “Early” CML diagnosis*, % | 46 |
| Baseline CML diagnosis, % chronic phase/% accelerated phase | 85/15 |
| New CML (Hasford) risk score†at diagnosis,20 % | |
| Low risk | 55 |
| Intermediate risk | 36 |
| High risk | 9 |
| Additional cytogenetic abnormalities at baseline, % | 13 |
| Median percentage of Ph-positive metaphases at baseline (25%-75% levels) | 100 (95-100) |
| Average imatinib mesylate dose, mg/d | |
| Chronic phase | 450 |
| Accelerated phase | 590 |
| Other concomitant therapies, with imatinib mesylate, % | |
| None | 65 |
| IFN or Ara-C | 31 |
| Tipifarnib | 1 |
| Donor leukocytes | 1 |
| Hsp70 vaccine | 1 |
| Median time from start of imatinib mesylate to CCR, mo (range) | 9.5 (2.4-57) |
| Median time from start of imatinib mesylate to major cytogenetic response‡, mo (range) | 5.5 (1-57) |
| Median time of follow-up after imatinib mesylate, mo (range) | 29 (8-59) |
| Median time of follow-up after CCR, mo (range) | 13 (0-32) |
| Median interval between monitoring visits, mo (range) | 3.2 (0.1-21) |
| Median number of laboratory monitoring visits (range) | 6 (1-16) |
Characteristic . | Value . |
|---|---|
| Median age, y (range) | 51.8 (20-74) |
| Sex, % male | 60 |
| Median time from leukemia diagnosis to start of imatinib mesylate, mo (range) | 8.9 (0-165) |
| “Early” CML diagnosis*, % | 46 |
| Baseline CML diagnosis, % chronic phase/% accelerated phase | 85/15 |
| New CML (Hasford) risk score†at diagnosis,20 % | |
| Low risk | 55 |
| Intermediate risk | 36 |
| High risk | 9 |
| Additional cytogenetic abnormalities at baseline, % | 13 |
| Median percentage of Ph-positive metaphases at baseline (25%-75% levels) | 100 (95-100) |
| Average imatinib mesylate dose, mg/d | |
| Chronic phase | 450 |
| Accelerated phase | 590 |
| Other concomitant therapies, with imatinib mesylate, % | |
| None | 65 |
| IFN or Ara-C | 31 |
| Tipifarnib | 1 |
| Donor leukocytes | 1 |
| Hsp70 vaccine | 1 |
| Median time from start of imatinib mesylate to CCR, mo (range) | 9.5 (2.4-57) |
| Median time from start of imatinib mesylate to major cytogenetic response‡, mo (range) | 5.5 (1-57) |
| Median time of follow-up after imatinib mesylate, mo (range) | 29 (8-59) |
| Median time of follow-up after CCR, mo (range) | 13 (0-32) |
| Median interval between monitoring visits, mo (range) | 3.2 (0.1-21) |
| Median number of laboratory monitoring visits (range) | 6 (1-16) |
N = 85. No significant difference was observed between patients with durable CCR (n = 62) and patients with disease progression (n = 23) for all listed variables. Percentages given in table are percent of total patients.
IFN indicates interferon-α; Ara-C, cytarabine.
< 6 months before imatinib mesylate.
Euro score.
Ph < 35%.